Products
Dalteparin is commercially available as an injectable (Fragmin). It has been approved in many countries since 1988.
Structure and properties
Dalteparin is present in drugs as dalteparin sodium, the sodium salt of a low-molecular-weight heparin obtained by depolymerization of heparin from porcine intestinal mucosa using nitrous acid. The average molecular weight is 6000 Da.
Effects
Dalteparin (ATC B01AB04) has antithrombotic and thrombolytic properties. The effects are primarily due to inhibition of coagulation factor Xa by complex formation with antithrombin III. Dalteparin has a longer half-life than standard heparin.
Indications
For prevention and treatment of thromboembolic disease.
Dosage
According to the SmPC. The solution for injection is usually injected subcutaneously. Some indications also require intravenous administration.
Contraindications
Refer to the drug label for complete precautions.
Interactions
Drug-drug interactions are possible with drugs that have an effect on blood clotting.
Adverse effects
The most common possible adverse effects include bleeding, pain, and bruising at the injection site.
